Excessive charity: A new aspect of impulse control disorders in Parkinson’s disease?

Otmani, Hicham El; Abdulhakeem, Zaynab; Moutawakil, Bouchra El; Bellakhdar, Salma; Rafai, M.A.

doi:10.1017/s1041610220000253

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, as research progresses, the clinical spectrum of ICBs is expected to expand further. Recent studies have reported that newly relevant behaviors, such as over-donation and over-indulgence in mobile devices, may be included within the scope of ICBs (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Assessing impulse control behaviors in early Parkinson’s disease: a longitudinal study

Zhu,

Gan,

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveImpulse control behaviors (ICBs) frequently coexist with Parkinson’s disease (PD). However, the predictors of ICBs in PD remain unclear, and there is limited data on the biological correlates of ICBs in PD. In this study, we examined clinical, imaging, and biological variables to identify factors associated with longitudinal changes in ICBs in early-stage PD.MethodsThe data for this study were obtained from the Parkinson’s Progression Markers Initiative, an international prospective cohort study that evaluates markers of disease progression in PD. We examined clinical, imaging, and biological variables to determine their associations with ICBs over a period of up to 5 years. Cox regression models were employed to investigate the predictors of ICBs in early-stage, untreated PD.ResultsThe study enrolled 401 individuals with PD and 185 healthy controls (HC). At baseline, 83 PD subjects (20.7%) and 36 HC (19.5%) exhibited ICBs. Over the course of 5 years, the prevalence of ICBs increased in PD (from 20.7% to 27.3%, p < 0.001), while it decreased in HC (from 19.5% to 15.2%, p < 0.001). Longitudinally, the presence of ICBs in PD was associated with depression, anxiety, autonomic dysfunction, and excessive daytime sleepiness (EDS). However, there was no significant association observed with cognitive dysfunction or motor severity. Treatment with dopamine agonists was linked to ICBs at years 3 and 4. Conversely, there was no association found between ICBs and presynaptic dopaminergic dysfunction. Additionally, biofluid markers in baseline and the first year did not show a significant association with ICBs. A predictive index for ICBs was generated, incorporating three baseline characteristics: anxiety, rapid eye movement sleep behavior disorder (RBD), and p-tau levels in cerebrospinal fluid (CSF).ConclusionDuring the early stages of PD, there is a notable increase in ICBs over time. These ICBs are associated with depression, anxiety, autonomic dysfunction, EDS, and the use of dopaminergic medications, particularly dopamine agonists. Anxiety, RBD, and p-tau levels in CSF are identified as predictors for the incident development of ICBs in early PD. Further longitudinal analyses will provide a more comprehensive understanding of the associations between ICBs and imaging findings, as well as biomarkers. These analyses will help to better characterize the relationships and implications of these factors in the context of ICBs in early PD.

show abstract

Section: Introductionmentioning

confidence: 99%